Bainco International Investors increased its holdings in shares of Urogen Pharma Ltd (NASDAQ:URGN) by 44.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 104,961 shares of the company’s stock after purchasing an additional 32,500 shares during the quarter. Bainco International Investors’ holdings in Urogen Pharma were worth $5,204,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Urogen Pharma during the 4th quarter worth about $166,000. State of Tennessee Treasury Department acquired a new stake in shares of Urogen Pharma during the 3rd quarter worth about $158,000. JPMorgan Chase & Co. acquired a new stake in shares of Urogen Pharma during the 3rd quarter worth about $168,000. MYDA Advisors LLC acquired a new stake in shares of Urogen Pharma during the 4th quarter worth about $223,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Urogen Pharma during the 4th quarter worth about $234,000. 50.48% of the stock is owned by hedge funds and other institutional investors.
A number of analysts recently issued reports on the company. Cowen reissued a “buy” rating on shares of Urogen Pharma in a research report on Wednesday, November 15th. UBS Group cut Urogen Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 15th. Raymond James Financial cut Urogen Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 15th. Oppenheimer set a $51.00 target price on Urogen Pharma and gave the company an “outperform” rating in a report on Tuesday, November 14th. Finally, CIBC restated an “outperform” rating and set a $51.00 target price (up from $32.00) on shares of Urogen Pharma in a report on Wednesday, November 15th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $39.00.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3256741/urogen-pharma-ltd-urgn-position-increased-by-bainco-international-investors.html.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma Ltd (NASDAQ:URGN).
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.